SCHEMBL15601792

SCHEMBL15601792

Cc1cccc(COC(=O)N(C)CCC(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
POLB P06746 1/20 0.48
MMP2 P08253 1/20 0.48
MMP9 P14780 1/20 0.48
MMP12 P39900 1/20 0.48
FFAR1 O14842 2/20 0.45
HSP90AA1 P07900 2/20 0.44
LTB4R Q15722 1/20 0.43
LTB4R2 Q9NPC1 1/20 0.43
MAOB P27338 2/20 0.43
IDO1 P14902 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164180 0.86 ALDH1A1 (0.51) KMT2ANPC1RAB9AL3MBTL1
SCHEMBL15592215 0.83 LMNA (0.43) MEN1KMT2ACYP4F2CYP4A11RAB9A
SCHEMBL15601765 0.82 MMP2 (0.46) POLBMMP2MMP9MMP12HSP90AA1
SCHEMBL21071646 0.82 MMP2 (0.46) THRATHRBFFAR4POLBMMP2
SCHEMBL13291290 0.80 FFAR4 (0.48) THRATHRBFFAR4POLBMMP2
SCHEMBL4890734 0.79 THRA (0.54) THRATHRBFFAR4POLBMMP2
SCHEMBL393422 0.77 HTT (0.52) KMT2ANPC1RAB9AL3MBTL1
SCHEMBL27771970 0.77 POLB (0.54) THRATHRBFFAR4POLBMMP2
SCHEMBL15601798 0.77 HTT (0.59) THRATHRBFFAR4POLBMMP2
SCHEMBL9698980 0.77 CCR6 (0.53) KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 US disclosed
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 THRA 87/4885THRB 49/4885FFAR4 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.